Angiotensin II-Receptor Antagonists: An Overview

Raquel Dina and Mahtab Jafari

Am J Health Syst Pharm. 2000;57(13)

Tasosartan

The new drug application for tasosartan was withdrawn in March 1998 because of unresolved questions about safety, specifically liver toxicity that occurred in 12% of patients in Phase II and Phase III clinical trials.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Next Section

Cite this: Angiotensin II-Receptor Antagonists: An Overview - Medscape - Jul 01, 2000.

Table 1. Comparison of Angiotensin II-Receptor Antagonists
Drug	Active Metabolite	Bioavailability (%)	Daily Dose (mg)	Half-life (hr)	Cost ($)a
Losartan	Yes	33	25-100	2 (losartan) 6-9 (EXP-3174)	38
Valsartan	No	25	80-320	6	36
Irbesartan	No	60-80	150-300	11-15	36
Candesartan	No	42	8-32	3-4 3-11	36
Eprosartan	No	13	600-800	5-9	37
Telmisartan	No	42-58	20-80	24	39

a Estimated cost, based on average wholesale price (Drug Topics Red Book, 1999), to the pharmacist for a one-month supply at the usual starting dosage.

Table 2. Clinical Trials Comparing Angiotensin-II-Receptor Antagonists with Angiotensin-Converting-Enzyme Inhibitors a
a	Losartan dosages are expressed in terms of losartan potassium, and candesartan dosages are expressed in terms of candesartan cilexetil. BP = blood pressure, SBP = systolic blood pressure, DBP = diastolic blood pressure, NR = not reported, HCTZ = hydrochlorothiazide.
b	Primary efficacy variable was assessed after eight weeks of therapy.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Angiotensin II-Receptor Antagonists: An Overview

Tasosartan

Tables

Tables

References

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback